serum
specimen
suspectedprob
sar
patient
admit
major
hospit
beij
area
april
june
elig
inclus
serum
procur
data
manag
blood
collect
protocol
approv
beij
sarscontrol
work
group
accord
biosafeti
guidelin
among
retrospect
sampl
select
probabl
patient
whose
blood
sampl
collect
onset
fever
within
day
time
admiss
acut
sar
patient
tabl
probabl
case
base
elig
criteria
set
forth
case
also
radiograph
evid
infiltr
consist
pneumonia
respiratori
distress
syndrom
chest
xray
pair
convalesc
serum
sampl
sar
cohort
test
posit
igm
seroconvers
ifa
method
beij
genom
institut
four
sampl
also
test
posit
dna
array
test
use
nasopharyng
sampl
nonsar
control
serum
sampl
tabl
obtain
recruit
healthi
donor
n
patient
respiratori
infect
pneumonia
n
high
fever
n
influenza
lung
cancer
n
control
sampl
neg
sarscov
seroconvers
patient
serum
sampl
divid
two
group
one
train
set
blind
test
set
tabl
sar
nonsar
control
sera
store
aliquot
round
mass
spectrometr
assay
routin
perform
qualiti
control
serum
sampl
appear
peak
intens
mz
fig
peak
intens
mz
remain
rel
constant
among
spectra
differ
assay
differ
instrument
also
use
normal
round
analys
three
differ
chip
chemistri
hydrophob
anion
cation
first
evalu
determin
affin
chemistri
gave
best
serum
profil
term
number
resolut
protein
weakli
cation
exchang
chip
wcx
gave
best
result
mass
spectra
kda
wcx
chip
bioprocessor
format
ciphergen
chosen
allow
larger
volum
serum
chip
array
bioprocessor
pretreat
mmoll
sodium
acet
ph
platform
shaker
rpm
min
excess
sodium
acet
remov
invert
bioprocessor
paper
towel
process
repeat
twice
serum
sampl
thaw
ice
biosafeti
level
ii
cabinet
sampl
mix
buffer
moll
urea
gl
chap
phosphatebuff
salin
eppendorf
tube
vortexmix
min
ad
buffer
buffer
dilut
ninefold
ml
buffer
plu
ml
trishcl
mmoll
trishcl
ph
serumurea
mixtur
vortexmix
min
stop
reaction
addit
sodium
acet
ice
appli
serumurea
sampl
well
bioprocessor
seal
shaken
platform
shaker
rpm
min
excess
serumurea
solut
discard
bioprocessor
wash
three
time
mmoll
sodium
acet
describ
chip
remov
bioprocessor
wash
twice
deioniz
water
airdri
subsequ
eam
sinapin
acid
satur
mll
gl
trifluoroacet
acid
ad
well
airdri
sinapin
acid
applic
repeat
chip
place
protein
biolog
system
ii
pb
ii
mass
spectromet
reader
ciphergen
tof
spectra
gener
averag
laser
shot
collect
posit
mode
set
lowenergi
read
set
high
mass
kda
optim
kda
laser
intens
detector
sensit
focu
optim
center
highenergi
read
set
high
mass
kda
optim
kda
laser
intens
detector
sensit
mass
accuraci
calibr
extern
use
allinon
peptid
molecular
mass
calibr
ciphergen
sera
healthi
control
individu
appli
seven
bait
surfac
eight
chip
run
interv
analysi
withinrun
reproduc
parallel
sampl
sar
patient
patient
fever
patient
pneumonia
health
control
appli
duplic
singl
chip
run
two
differ
instrument
pb
ii
pb
iic
ciphergen
betweenrun
analysi
instrument
drift
avoid
possibl
placement
run
order
sampl
would
affect
assay
accuraci
sampl
load
chip
rotat
fashion
brief
sampl
spot
direct
chip
well
h
duplic
well
b
well
g
h
second
chip
sampl
load
chip
rotat
order
also
random
order
chip
placement
spectromet
minim
bia
run
order
spectra
collect
sampl
analyz
independ
use
classif
algorithm
establish
train
step
peak
mz
qualitycontrol
serum
adjust
intens
pb
ii
pb
iic
peak
intens
mz
qualitycontrol
serum
use
normal
instrument
resolut
pb
ii
pb
iic
normal
spectra
use
total
ion
current
ident
normal
coeffici
low
mass
cutoff
da
factor
normal
total
ion
current
peak
mz
repeat
run
would
perform
outlier
reject
test
root
biomark
mz
yield
lowest
similar
p
valu
pb
ii
pb
iic
peak
detect
perform
biomark
wizard
softwar
ciphergen
mz
ratio
select
analysi
rang
contain
major
resolv
protein
peptid
mz
rang
elimin
analysi
avoid
interfer
adduct
artifact
energyabsorb
molecul
possibl
chemic
contamin
peak
detect
involv
baselin
subtract
mass
normal
use
common
calibr
peak
mz
normal
total
ion
current
intens
minimum
mz
use
extern
normal
coeffici
normal
factor
individu
spectrum
ion
current
spectrum
spectra
obtain
differ
time
locat
set
use
autodetect
peak
cluster
first
pass
signaltonois
ratio
minimum
peak
threshold
spectra
peak
cluster
complet
secondpass
peak
detect
use
signaltonois
ratio
mass
cluster
window
averag
peak
detect
spectrum
mass
rang
kda
analyz
parallel
data
analysi
process
use
studi
involv
three
stage
peak
detect
align
b
select
peak
highest
discriminatori
power
c
data
analysi
use
decis
tree
algorithm
random
sampl
acut
sar
fever
pneumonia
lung
cancer
healthi
two
strata
acut
sar
nonsar
use
separ
entir
data
set
train
test
data
set
train
data
set
consist
seldi
spectra
acut
sar
nonsar
serum
sampl
valid
accuraci
classif
algorithm
challeng
blind
test
data
set
consist
acut
sar
nonsar
sampl
construct
decis
tree
classif
algorithm
perform
describ
previous
modif
base
biomark
pattern
softwar
ciphergen
classif
tree
split
two
branch
node
use
one
rule
time
set
target
variabl
level
minimum
valu
decis
made
base
presenc
absenc
intens
one
peak
use
gini
two
method
favor
even
split
vari
time
vfold
crossvalid
chang
growth
tree
lowest
cost
tree
valu
gini
vfold
select
final
test
identifi
serum
biomark
could
distinguish
sar
nonsar
sampl
use
train
set
specimen
sar
acut
control
tabl
construct
decis
tree
classif
algorithm
use
peak
peak
spectra
statist
signific
identifi
low
energi
read
see
materi
method
classif
algorithm
use
four
peak
kda
mz
gener
five
termin
node
fig
discriminatori
peak
effici
split
sar
specimen
termin
node
nonsar
sampl
termin
node
mass
peak
show
mean
intens
ratio
sar
vs
nonsar
p
valu
close
tabl
notabl
protein
peptid
mass
da
upregul
patient
acut
sar
wherea
mass
da
downregul
compar
healthi
control
patient
respiratori
tract
infect
repres
spectrum
sar
specimen
align
healthi
control
fig
show
four
fingerprint
node
requir
pattern
recognit
classifi
uniqu
presenc
root
biomark
mz
demonstr
align
repres
spectra
sampl
patient
acut
sar
day
onset
fever
termin
node
healthi
control
patient
fever
influenza
pneumonia
fig
decis
algorithm
correctli
classifi
acut
sar
sampl
nonsar
control
train
set
tabl
classifi
use
mass
lowenergi
read
mz
exhaust
meaning
serum
biomark
expand
analysi
train
sampl
highenergi
set
mz
kda
see
materi
method
pool
low
highenergi
read
togeth
peak
classif
algorithm
use
five
peak
kda
mz
peak
mz
overlap
fig
six
termin
node
yield
sensit
specif
respect
data
shown
peak
mz
new
classifi
disappear
correspond
peak
intens
beyond
limit
normal
intens
peak
mz
see
section
patient
sampl
materi
method
howev
sar
case
altern
classifi
fell
termin
node
proteinspeptid
downregul
mz
mz
mz
algorithm
combin
two
energi
set
analysi
reason
decis
tree
gener
lowenergi
read
fig
would
sensit
conveni
clinic
applic
determin
reproduc
seldi
spectra
mass
locat
intens
array
array
singl
chip
intraassay
instrument
interassay
first
spot
serum
healthi
control
seven
bait
singl
chip
collect
seven
independ
spectra
time
span
day
fig
select
seven
protein
rang
kda
mz
black
arrow
fig
calcul
intraassay
cv
peak
select
proxim
four
biomark
compar
current
intens
interassay
experi
similar
except
sera
healthi
control
patient
high
fever
pneumonia
sar
appli
singl
chip
independ
spectra
collect
two
differ
instrument
pb
ii
pb
iic
fig
b
c
mean
intra
interassay
cv
peak
locat
respect
consid
mass
accuraci
within
spectra
mean
intra
interassay
cv
normal
intens
respect
cv
calcul
use
lower
intens
peak
fig
gray
arrowhead
hand
yield
result
similar
obtain
seven
highintens
peak
peak
locat
intra
interassay
cv
peak
intens
intraassay
cv
interassay
cv
analysi
spectra
complet
blind
test
set
acut
sar
control
tabl
accur
classifi
sar
specimen
accur
classifi
control
nonsar
tabl
import
classif
algorithm
success
distinguish
acut
sar
fever
influenza
sensit
specif
reach
influenza
respect
interestingli
test
classifi
use
addit
control
popul
sampl
patient
beij
area
measl
juli
histori
close
contact
sar
patient
visit
hospit
treat
sar
patient
classifi
specif
confid
interv
data
shown
sever
laboratori
test
base
either
viral
rna
serolog
develop
complement
clinic
characterist
epidemiolog
data
identif
sar
earli
detect
sar
suffici
high
sensit
specif
achiev
identif
proteinspeptid
pathophysiolog
signific
phenom
fingerprint
crude
biolog
clinic
sampl
selditof
ms
demonstr
variou
cancer
studi
use
similar
profil
strategi
establish
classif
algorithm
delin
probabl
sar
patient
earli
day
selfdescrib
onset
symptom
healthi
individu
patient
respiratori
tract
infect
train
set
sensit
specif
appli
blind
test
set
discriminatori
profil
method
precis
classifi
patient
acut
sar
nonsar
patient
strikingli
classifi
abl
discrimin
sarscov
infect
bacteri
mycoplasma
tuberculosi
local
influenza
system
measl
viral
infect
respiratori
tract
specif
reach
attribut
inclus
correspond
inflammatori
control
sampl
train
set
optim
classif
algorithm
biomark
identifi
acut
phase
sar
seem
remain
throughout
convalesc
phase
diseas
appli
ident
tree
classif
sampl
patient
onset
fever
week
previous
could
detect
sar
sensit
specif
reach
respect
data
shown
one
intrigu
observ
sar
patient
cluster
termin
node
demonstr
moder
clinic
featur
wherea
node
sever
case
investig
correl
proteom
pattern
patholog
sar
result
repres
best
knowledg
accur
laboratori
techniqu
earli
detect
sar
pcrbase
assay
maximum
sensit
use
test
nasopharyng
aspir
plasma
specimen
proteom
method
describ
also
advantag
pcrbase
assay
requir
contain
detect
sar
serum
sampl
critic
altern
pcrbase
test
challeng
low
viral
load
nasopharyng
aspir
throat
swab
specimen
acut
phase
sar
instead
tradit
chromatograph
fraction
sampl
directli
spot
crude
serum
wcx
chip
avoid
unnecessarili
bias
deplet
thousand
protein
andor
peptid
associ
human
serum
albumin
ms
analysi
process
sampl
gener
diagnost
mass
spectra
method
requir
small
amount
serum
vs
sever
millilit
need
pcr
method
took
h
highthroughput
proteom
screen
sar
format
also
feasibl
adher
case
definit
elig
criteria
sar
avoid
use
sampl
nonsar
control
hospit
sar
patient
admit
person
might
histori
close
contact
sar
patient
insid
sar
hospit
emphas
point
sampl
control
sera
nonepidem
region
countri
although
possibl
might
exist
differ
serum
fingerprint
would
reflect
differ
among
sar
nonsar
hospit
fact
sar
case
differ
hospit
fit
singl
classif
algorithm
would
like
rule
concern
importantli
sever
mild
case
sar
differ
hospit
complet
random
experiment
analysi
fell
distinct
node
tree
classif
strongli
indic
biomark
identifi
specif
sar
site
blood
sampl
collect
minim
potenti
sampl
bia
simultan
use
four
biomark
instead
one
eg
mz
nevertheless
could
suffici
delin
sar
nonsar
sensit
specif
data
shown
sar
nonsar
sampl
patient
ethnic
background
sar
nonsar
control
sera
collect
differ
time
freshli
aliquot
properli
store
differenti
protein
pattern
discrimin
sar
nonsar
independ
protein
ident
origin
full
ident
discrimin
biomark
investig
know
ident
purpos
differenti
diagnosi
absolut
requir
shown
numer
studi
show
diagnosi
cancer
seldi
method
howev
character
peak
would
certainli
help
understand
biolog
role
peptideprotein
could
potenti
lead
discoveri
direct
diagnost
tool
novel
therapeut
target
sarscov
abbrevi
sar
sever
acut
respiratori
syndrom
cov
coronaviru
selditof
ms
surfaceenhanc
laser
desorptionion
timeofflight
mass
spectrometri
pb
protein
biolog
system
